71 results
6-K
EX-99.1
GLPG
Galapagos NV
13 Jan 20
Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis
6:06am
EXHIBIT 99.1
Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis
Mechelen, Belgium; 13 January 2020, 7.30 CET … – Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the PINTA Phase 2 clinical trial with oral GPR84 inhibitor GLPG1205.
PINTA
6-K
EX-99
GLPG
Galapagos NV
25 Jul 19
Strong clinical progress in H1, and transformative collaboration with Gilead announced
4:24pm
Completed recruitment of ROCCELLA Phase 2b trial with GLPG1972 in osteoarthritis, with Servier
Initiated GECKO Phase 2 trial in atopic dermatitis … starts, completion of recruitment in ROCCELLA, and our first Phase 1 trial from the next-generation Toledo program for inflammation.”
“Our financial
6-K
EX-99.1
GLPG
Galapagos NV
11 May 20
Current report (foreign)
4:05pm
of later stage clinical trials throughout the remainder of 2020. As a consequence of COVID-19 measures, patient recruitment in some Phase 2 and 3 studies … with filgotinib is temporarily halted, and we see an impact on recruitment rates of the ISABELA Phase 3 program with ziritaxestat (GLPG1690) in IPF
6-K
EX-99.1
GLPG
Galapagos NV
29 Nov 21
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
6:00am
EXHIBIT 99.1
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Mechelen, Belgium; 22 … November 2021, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational
6-K
EX-99.1
GLPG
Galapagos NV
12 Jun 23
Current report (foreign)
7:32am
was reported at DL2 with a patient experiencing a CRS grade 2, but the event was resolved after 7 days. Patient recruitment of the study is ongoing … visit is at Week 14 post CAR-T infusion. Phase 1 patient recruitment is ongoing to establish a recommended dose for Phase 2.
About chronic lymphocytic
6-K
EX-99.1
5w91t2vzwu ynuku
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
6-K
EX-99.1
xtu2ac
9 Dec 19
Galapagos completes recruitment of NOVESA trial in systemic sclerosis
10:11am
6-K
EX-99.1
697gg2b7nlxmtb7
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
lhuqpql nslcr8k
11 Jun 19
Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
6:05am
6-K
EX-99.1
3603t
18 Dec 18
Current report (foreign)
6:07am
6-K
EX-99.1
k4nlgiju
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.1
pwy60s0ssfdwfc0i
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.2
335kfyck wserpedu
11 May 20
Current report (foreign)
4:05pm
6-K
EX-99.1
temqijub8yci
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
7jhwlrgdwlj
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
vs7xjmrae
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.1
mvr19u2i
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.1
3ckvz5l5mascjxsgzh9x
26 Apr 19
Galapagos reports on historic first quarter 2019
4:06pm
6-K
EX-99.1
txma8z3 sl
25 Oct 19
Solid third quarter 2019 performance with strong balance sheet for continued R&D growth
5:00pm
6-K
EX-99.1
kvufh1
6 May 22
Current report (foreign)
5:18pm